When scientists discover they've been wrong about a disease, changing their minds is only half the battle. The other half is updating everything that came from that misunderstanding: the textbooks, the guidelines, the assumptions people carry around, and sometimes even the name of the disease itself.
That's exactly what's happening with Polycystic Ovary Syndrome (PCOS), which has officially been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS).
At first glance, this might seem like the sort of bureaucratic rebranding exercise that only medical professionals could get excited about. The scientific equivalent of Twitter becoming X. But the decision to rename PCOS goes much deeper than terminology: for decades, the name suggested a disorder defined by ovarian cysts. The problem is that ovarian cysts were never really the main story.
The Disease That Was Never Really About Cysts
Let's start with the obvious question. If PCOS wasn't accurately named, why was it called Polycystic Ovary Syndrome in the first place?
Because for a long time, physicians thought the characteristic structures visible on ovarian ultrasounds were cysts. The ovaries appeared to contain many small, round, fluid-filled structures, and thus "polycystic" seemed an apt descriptor. However, it turns out these structures aren't pathological cysts. What clinicians were seeing were arrested follicles: immature structures containing eggs that had begun developing but never completed the process. While they appear similar in imaging, they aren't cysts in the medical sense of the word. To make matters more confusing, ovaries that appear "polycystic" on ultrasound can also be found in people who don't have the condition at all.
In other words, the defining feature in the name wasn't particularly defining, and wasn't even technically accurate. Unfortunately, the confusion didn't stop there.
A Syndrome With an Identity Crisis
PCOS affects roughly one in eight women worldwide and is considered the most common endocrine disorder among reproductive-age females. Yet despite its prevalence, it has spent much of its history being misunderstood.
Part of the problem is that the name directs everyone's attention toward the ovaries, when the ovaries are only one piece of a much larger puzzle.
Today, diagnosis is based on a combination of features that can include irregular ovulation, elevated androgen levels, and polycystic appearing ovaries on ultrasound. But the condition extends far beyond reproductive health. Individuals with the syndrome often experience insulin resistance, metabolic dysfunction, increased risk of type 2 diabetes, cardiovascular disease, pregnancy complications, and a range of psychological and dermatological symptoms. That's a lot for a disease name to leave out.
When a Name Becomes a Problem
This might sound like semantics, but names have consequences. Medical terminology shapes how patients understand their conditions, how healthcare providers approach diagnosis, and even how research funding is allocated. Therefore, a misleading name can create misleading assumptions. Evidence suggests that may have happened in the case of PCOS.
Researchers have argued that the ovarian focus of PCOS contributed to what they call "siloed" care, where patients were treated primarily through a reproductive-health lens while important metabolic and cardiovascular risks received less attention.
Even among healthcare professionals, confusion persists. A large international study involving more than 7,700 patients and clinicians found that more than 20% of participants did not recognize important associations between PCOS and conditions such as fatty liver disease, cardiovascular risk factors, pregnancy complications, and endometrial cancer.
Enter PMOS
In May 2026, a group of international experts published an article in The Lancet that formally proposed the transition from PCOS to PMOS.
I’ll admit, Polyendocrine Metabolic Ovarian Syndrome doesn’t exactly roll off the tongue. But unlike the old name, this new one attempts to capture what researchers now understand about the disorder.
"Polyendocrine" acknowledges the multiple hormone systems involved. "Metabolic" reflects the central role of insulin resistance and metabolic dysfunction. "Ovarian" remains present because reproductive symptoms are still an important component of the disease. Together, the name paints a much more accurate picture of a multisystem condition.
This change didn't happen overnight. Discussions about replacing the term PCOS date back to a 2012 NIH workshop, where experts raised concerns about the limitations of the existing name. More recently, international surveys found that most patients and healthcare professionals supported a name change, with approximately 84% endorsing a consensus-driven process.
While The Lancet article got the ball rolling, the transition is expected to occur over several years.
More Than a Rebranding Exercise
Scientific progress doesn't just involve discovering new things. Sometimes it involves realizing we've been describing old things poorly. PMOS now joins a long tradition of science correcting itself.
By shifting attention away from the ovaries alone and toward the broader endocrine and metabolic realities of the condition, it is the hope that patients will receive earlier diagnoses, more comprehensive care, and a better understanding of the disease they are living with.
Sophie Tseng Pellar is a Masters Student in the Surgical and Interventional Sciences program at McGill. Her research interests include exercise physiology, biomechanics and sports nutrition.
Part of the OSS mandate is to foster science communication and critical thinking in our students and the public. We hope you enjoy these pieces from our Student Contributors and welcome any feedback you may have!
